ArticleScientific reports2025
Feasibility of long-read sequencing to identify molecular alterations in an Indonesian cohort of locally advanced to advanced nasopharyngeal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ClonalLife science alliance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia, particularly in Indonesia. Despite advances in treatment, patients with advanced NPC face poor outcomes. Examining the NPC mutational landscape is crucial for understanding its biology and enable potential new therapeutic strategy. To characterize the landscape of single nucleotide variants (SNVs), structural variants (SVs), copy number variations (CNVs), and short tandem repeats (STRs) in locally advanced to advanced NPC within an Indonesian cohort using long-read sequencing. Six fresh-frozen nasopharyngeal biopsy samples were collected from the NPC biobank. DNA was extracted and sequenced using Oxford Nanopore's Promethion 2 Solo long-read sequencer. Structural and small variants were identified and annotated. The SNVs, SVs, and CNVs were categorized based on predicted effects, and key findings were validated using external RNA-seq data. Copy number loss genes were checked against the Tumour Suppressor Gene database (TSGene v2.0). Genetic findings were correlated with patient clinical histories. Approximately 4.4 to 5.1 million SNVs were identified per sample, with 0.023% categorized as high consequence. Notable tumour suppressor genes, such as LIMD1 and CNDP2, were frequently mutated. Around 30,000 to 41,599 SVs were detected per sample. High-consequence tumour suppressor gene SVs were identified in EPHA3, CASP8, DMBT1, ZFHX3, and IRF5 gene. Common copy number tumour suppressor gene loss observed in RNH1, H19, CDKN1C, and others, suggesting their role in NPC carcinogenesis. Copy number gains were found in potential oncogenes such as Y RNA, LTO1, and FADD. Pathogenic short tandem repeats (STRs) in PABPN1 and RFC1 were identified in three samples, presenting a novel association with NPC. NPC sample which exhibited significant genomic instability had the shortest survival, potentially linked to multiple defective DNA repair genes. This study utilized long-read sequencing to identify a complex spectrum of genetic alterations, including numerous SVs and potentially pathogenic STRs, in Indonesian NPC. Extensive DNA repair gene defects, primarily complex SVs detectable by long reads, were observed and highly possibly associated with poor survival. These findings underscore the potential of long-read sequencing for uncovering clinically relevant mutations in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.